As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...

After months of searching for strategic options, Adaptimmune is offloading its cell therapies to a global pharma, which plans ...

The strategic reprioritization comes after the company hit two major hurdles in the past year, including a clinical hold for ...

Since Dr. Vinay Prasad’s appointment as a key political voice within FDA, the tone of U.S. biotech policy has shifted from ...

Commissioner Marty Makary says the FDA will plow ahead with big plans on ultra process foods, dietary guidelines and ...

This Massachusetts-based biopharmaceutical company announced hundreds of layoffs last week. Here's what the CEO said about it ...

Last Monday, the U.S. Department of Health and Human Services (HHS) finalized 10,000 layoffs across federal health agencies, including the National Institutes of Health (NIH), U.S. Food and Drug ...

Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

A Massachusetts biotechnology company is laying off 21 employees in Durham amid a broader restructuring and pressure from federal regulators.

FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency’s Center for Drug Evaluation and Research, which regulates the safety and ...

The Sarepta saga continues, with the FDA slapping a clinical hold across all of the company’s investigational limb-girdle ...

A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.